Triptorelin Acetate Injection

Triptorelin is a synthetic analog of gonadotropin-releasing hormone (GnRH). The structural modification is to replace the sixth L-amino acid (glycine) in the natural molecular structure with D-tryptophan. Triptorelin has the same effect as GnRH, but its plasma half-life is prolonged and its affinity for GnRH receptors is stronger, so triptorelin becomes a strong agonist of GnRH receptors. After injection, triptorelin initially stimulates the pituitary gland to secrete gonadotropins (Gn), namely luteinizing hormone (LH) and follicle-stimulating hormone (FSH). When the pituitary gland enters a refractory period after long-term stimulation, the release of gonadotropins will decrease, thereby reducing sex steroids (testosterone or estrogen) to castration levels. The above effects are reversible.

Triptorelin acetate.

This product is a colorless clear liquid.

1. Assisted reproductive technology (ART), such as in vitro fertilization (IVF). 2. Hormone-dependent prostate cancer. 3. Precocious puberty. 4. Endometriosis. 5. Uterine fibroids.

Common dose: 0.5 mg subcutaneously once a day for seven consecutive days; then 0.1 mg subcutaneously once a day as a maintenance dose. In vitro fertilization (IVF): The dose is based on the clinical plan. Usually, 0.1 mg of Johnson (triptorelin) is injected subcutaneously or intramuscularly every day starting on the first day of the treatment cycle until hCG is given.

Possible pharmacological side effects due to suppressed hormone production include: Male: hot flashes, impotence and loss of libido. Female: hot flashes, vaginal dryness, dyspareunia, spotting and possible slight loss of trabecular bone matrix due to the reduction of estrogen blood concentration to post-menopausal levels. However, full recovery to normal is generally achieved six to nine months after treatment is stopped. Other rare side effects: local reactions at the injection site, mild allergic symptoms (fever, itching, rash, anaphylaxis), gynecomastia, spotting, headache, fatigue and sleep disturbance. The above side effects are generally mild and will disappear after stopping the drug.

1. Triptorelin should not be used in patients with non-hormone-dependent prostate cancer or after prostatectomy. 2. Patients who are allergic to any component of this product or to gonadotropin-releasing hormone (GnRH) and its analogs are contraindicated. 3. During treatment, if the patient is found to be pregnant, the use of triptorelin should be stopped.

Precautions for children: Not for children. Precautions for pregnancy and lactation: 1. Hydroureteral accumulation may occasionally occur after direct injection of high-dose triptorelin into the uterus of young rats. In controlled trials of assisted reproductive treatment, Dabiq is often used to suppress endogenous gonadotropin and estrogen levels. If pregnancy is diagnosed, Dabiq treatment should be terminated immediately. 2. It is not clear whether triptorelin enters breast milk, but Dabiq can cause a slight decrease in prolactin, thereby reducing milk production. Precautions for the elderly: No dosage adjustment is required.

No interactions with other drugs have been reported.

Store below 8°C.

1 ml: 0.1 mg (95.6 μg based on triptorelin)

Valid for 3 years.